EGFR and neoplasm: Patients with concurrent EGFR mutations in pretreatment plasma have shorter PFS (HR = 2.00, 95% confidence interval [CI]: 1.73–2.31, p < .001) and OS time (HR = 2.31, 95% CI: 1.89–2.83, p < .001) compared to the tumor‐only mutation cases.